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ABSTRACT 
The novel coronavirus disease 2019 (COVID-19) was characterized as a global pandemic by the World Health Organization (WHO) on March 11, 
2020. The present pandemic has caused an intolerable impact on the health structure as well as the pharmaceutical sector, which in ultimatum has 
created enormous issues in the everyday lives of the patient community. On the other hand, the situation may appear in short and long-term time-
horizon and need identification along with appropriate planning to reduce their socio-economic burden. The Indian pharmaceutical industry is the 
world's third-largest drug producer by volume. India supplies affordable and low-cost generic drugs to millions of people around the globe and 
operates more than 250 United States Food and Drug Administration (USFDA) and United Kingdom Medicine and Healthcare products Regulatory 
Agency (UKMHRA) approved plants. Given the Indian pharmaceutical industry, the source of Active Pharmaceutical Ingredients (APIs) for multiple 
diseases is much crucial part of the Pharma industry’s strategic plan to combat the COVID-19 pandemic. China is the top global producer and 
exporter of APIs by volume and Indian pharmaceutical industries are also rely heavily on APIs from China for the production of their medicine 
formulations by importing around 70 percent of the total requirement. However, the present pandemic situation has exposed the world's over-
reliance on China in terms of API import and bound world leaders to fig. out sustainable alternatives.  
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INTRODUCTION 
The review of literature related to the present systematic review 
study was carried out in the period from April 2020 to October 
2020. The search terms used were ‘active pharmaceutical 
ingredients’, ‘coronavirus’, ‘pharmaceutical industry’, ‘COVID-19’, 
‘Indian API scarcity', pharmaceutical raw material', 'growth 
development index', ‘future proposal of API industry'. The present 
search and study were carried out by referring to various journals 
containing peer review and research papers and the latest scientific 
magazines and electronic media publications. The electronic 
databases used were Science Direct, Pub Med, Web of Science, 
Scopus which provides free access to Medline, Google and Google 
scholar. Only published contents in English languages were used for 
the more comprehensive study to make the latest review article on 
API Scarcity during the coronavirus pandemic. Reference lists of 
articles were also cross-checked for authentication. 
Active Pharmaceutical Ingredients (APIs) means the effective 
ingredient which is contained in the medicine. For instance, 
considering the case of the commercially available pharmaceutical 
product from any company which is used to reduce normal body 
ache and fever, the API Paracetamol is the active pharmaceutical 
component contained in the product that gives relief from body ache 
and fever for which the mentioned medicine is prescribed or taken. 
Whereas, fixed-dose combination drug use several APIs, while 
single-dose drugs were made of just one APIs [1, 2]. 
A very small amount of the active ingredient can be able to produce 
therapeutic effects. Thus, only a small part of the active ingredient is 
generally contained in the medicines. Nevertheless, APIs and raw 
materials are frequently confusing due to the similar usage of both 
the terms. Raw material relates to chemical compounds that are 
used as a base to make an API. Whereas, the API is not only made by 
a single reaction from the raw materials but rather it becomes an 
API via several chemical compounds. The chemical compound which 
is in the process of coming to be an API from raw material is called 
an ‘intermediate’. There are also some APIs that involve more than 
ten kinds of intermediates in a process related to the conversion of 
raw materials into an API [1, 3]. 
Apart from APIs, a medicine contains chemically inactive 
components termed as ‘excipients’ which do the job of delivering the 
effect of APIs to the human body system. An API manufacturer first 
develops the chemical compound in a laboratory after which the 
production department manufactures a bulk amount of APIs using 
large size reactors. Finally, these are checked for purity, before 
selling it to the drug makers. The quality of an API is one of the most 
important factors in view of appropriate effectiveness of the 
medicine. Furthermore, the active pharmaceutical ingredients (APIs) 
market in our country is forecasted to attain revenue of $6 billion by 
the end of 2020 [2-4]. 
Impact of covid-19 pandemic 
The world is now in an alarming situation amid the pandemic 
coronavirus disease and due to which it has been shown that there is a 
huge scarcity regarding APIs which are very much integral parts to 
make medicine or medical products [3, 4]. The Indian pharmaceutical 
industry is highly dependent on China. About 70% of raw materials for 
APIs in India are imported from China [5]. But the periodic lockdowns 
prevailing in both the countries due to the COVID-19 pandemic 
situation has a massive negative impact on the international supply 
and export-import of goods.–The bilateral relations between both 
countries are aggressively turning day by day towards an enmity. 
Thus, all these factors are constructively contributing to the APIs 
scarcity in India in a very significant way [1, 4, 6]. 
Due to this pandemic outbreak, supplies of raw materials from China 
to produce drugs for treating chronic diseases like HIV, cancer, 
epilepsy, malaria, and even many commonly used antibiotics and 
vitamin pills, were affected the most. Industry insiders panic that the 
coronavirus created supply constraints that may lead to shortages of 
cardiovascular and antibiotic categories of drugs [2, 5, 7]. The 
domestic pharmaceutical industry is highly dependent on imports 
with more than 60 percent of its API requirement being shipped 
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inand in some specific cases active pharmaceutical ingredients like 
cephalosporins, azithromycin, and penicillin. Because the 
dependence is as high as 80 to 90 percent. Moreover, supply-side 
constraints and risks of contamination are also expected to add fuel 
to the shortages of certain kinds of medicines [6, 8]. 
The COVID-19 pandemic situation resulted in immense cost 
increases in drugs. For instance, Penicillin's raw material became 40 
percent costlier in just a month. According to data from the 
Pharmaceutical Export Promotion Council (PHARMEXCIL), which 
functions under the Ministry of Commerce and Industry, the cost of 
API Penicillin has increased to Rs. ₹639.00 ($8.69) per unit at the 
time of writing this article, against Rs. ₹
The Indian regulatory agency predicts that more than 50 APIs of 
crucial antibiotics, vitamins, and hormones or steroids could go out 
of stock in case of a prolonged lockdown in China. ‘Montelukast 
sodium’ (an anti-asthmatic drug) is now trading between Rs. 
454.00 ($6.16) per unit in 
January 2020. [9, 10]. Data collected by API manufacturers further 
suggests that there is a rise of 13 to 18 percent in the prices of APIs 
for other antibiotics such as Azithromycin, Doxycycline, Amikacin, 
Ornidazole, and Dexamethasone Sodium, etc. and India imports most 
of them from China. Meanwhile, the price of Paracetamol, an API 
widely used as painkiller and during fever has increased by 26 
percent in January [11-13]. 
₹52,000 Rs. ₹58,000 ($705.93-$787.38) per kg, compared to Rs. 
₹
India’s drug pricing regulator has allowed pharmaceutical companies 
to raise the ceiling price of essential medicine like heparin by 50 
percent until December 31, 2020. Heparin is an anticoagulant or 
antiplatelet drug that has long been used in patients vulnerable to 
blood clots in their legs, lungs, heart, or other body parts. It is used to 
reduce the risk of heart attacks, strokes, and lung or pulmonary 
embolism. Several patients with critical illnesses, including those 
requiring dialysis or kidney, are given the drug [18, 19]. 
33,000 to Rs. 38,000 ($447.99-$515.87) per kg a few months ago. 
Similarly, the prices of vitamins and penicillin have increased by 40-
50 percent and the majorities of the vitamins are trading at double 
or triple the original price [14, 15, 16]. The companies may end up 
exhausting most of their stock of active ingredients for high-demand 
of drugs like Paracetamol and Ibuprofen. Moreover, the impact is set 
to be grave, as most of those materials are largely manufactured in 
the Hubei province whose capital, Wuhan has been the initial 
epicenter of the COVID-19 outbreak. The neighboring areas of 
Zhejiang and Jiangsu are the other two major Chinese centers of 
medicinal raw material production. Hubei province supply 30 to 
40 categories of basic chemicals, APIs, intermediates to India and 
about Rs. 17,400 crore APIs have been imported from all over 
China. [9, 17]. 
During the Covid-19 pandemic, the Ministry of Health and Family 
Welfare (MoHFW) included the drug in its clinical management 
guidelines for the treatment of Covid-19 patients in the Intensive 
Care Units. Still, there have been instances of deficiency of this drug 
during this pandemic situation. National Pharmaceutical Pricing 
Authority (NPPA) used extraordinary emergency powers provided 
to it under paragraph 19 of the Drugs Prices Control Order (DPCO), 
2013. This is for the first time that NPPA increased the prices of 
medicines under the price control by 50 percent in comparison to 
December 2019. The prices of 21 numbers of drugs were increased, 
which are integral to various public health programs and often used 
as the first line choice of treatment [15, 20]. 
 
Table 1: World-wide impact of COVID-19 on the pharmaceutical sector 







Covid-19 related ↑in10% of OTC category 
(cold and cough) drugs 
↑ in10% of OTC 
category (vitamins, 
minerals, etc.)  
Investigational treatments 
have seen a 2-fold ↑ 
21 
↑403% in Personal hygiene ↑in 62 % of personal 
hygiene 
Medicines used in hospitals 
for the treatment of Covid-19 
have ↑ between 100% and 
700% since January 2020 
 
↑in67% of ICU medications    
General like Panic 
buying 
↑in23% of Lipid-lowering 
drugs 
↑in7% of highest 
volume growth in 
ATCN class of Rx-
category in Spain 
Excess of prescriptions for 
hypertension-7, Mental 
health-6, Respiratory-5, 




- -  
↑in29.1% of 
antihypertensive drugs 
- -  
Shortage of supply Medicines for chronic 
diseases were at high risk of 
shortage or supply chain. 
- The supply shortage of both 
active APIs and finished 
products 
 
- - - The supply shortage of Covid-
19 related complications 
treatment 
 
Research and development Shifts 156 clinical trials are 
running for Covid-19 
140 clinical trials are 




WhatsApp call is the 
most preferred digital 
channel for both 
communications 
↑ in 320% (v. PY) in remote 
interactions in Spain. The ↑in 
Italy (v. PY) was 471% 
70-80% ↓in the 
number of patient 
visits to doctors 
-  
- Digital channel has 
wide adoption with 
over 75% 
↓ in 51%in specialist 
consultations and ↓in 25 % in 
GPs visits 
Tele-medicine 
growth accounts for 







Clinical trial 8% delay 
existing enrolment 
Pharma companies report a 
delay in new trial starts  
- -  
- 16% delay new trials 
only 32% delay new 
trials and existing 
patient enrolment 
Product launches delayed, 
disrupted, or impacted 
- -  
Shifts towards self-
sufficiency in the 
pharma industry 
- Direct investment and free 
movement of capital 
- -  
v. PY: versus Previous Year, APIs: Active Pharmaceutical Ingredients, OTC: Over the Counter, ATCN: Anatomical Therapeutic Chemical Classification 
Nervous system, GPs: General Practitioners, RandD: Research and Development, ICU: Intensive Care Unit, EU: European countries, ↑: Increase, ↓: 
Decrease. 
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Such important drug includes, Bacilli Calmette-Guerin (BCG) vaccine for 
tuberculosis disease, vitamin C, antibiotics like metronidazole and 
benzylpenicillin, anti-malarial drug-like chloroquine, and leprosy 
medication like dapsone. The heparin sodium API for the manufacturing 
of injections in India was majorly comes from China. It means that a snag 
in the supply chain from China could disrupt the availability of medicines 
made in India and for the rest of the World. Such dependency will 
definitely hit the availability of medicines in other countries that imports 
from India as well. The shipments of drugs like paracetamol, 
erythromycin salts, Vitamins B1, B6, and B12, acyclovir, and 
progesterone were only allowed to import with a no-objection certificate 
(NOC) that companies claimed were difficult to procure. This was 
around the time that Wuhan province in China, from where these Active 
Pharmaceutical Ingredients were mostly imported, was under a strict 
COVID-19 pandemic lockdown. Table 1 represents the world wide 
impact of the COVID-19 pandemic on the Pharmaceutical sector [21]. 
 
 
Fig. 1: Proposed future strategies to make self-resilient India in API manufacturing [22] 
 
To combat the rapid rise in API prices during this pandemic, the 
Indian pharmaceutical industry needs to develop and implement a 
robust strategy very quickly. Policy makers should first start by 
setting short term goals. The existent domestic players must be 
improved and incentivized to eventually set them up for the global 
competition in the long term. Most of the focus must be on ease of 
doing business which will invite more startups and manufacturers to 
the indigenous pharmaceutical field. The long-term goal must be to 
become self-sufficient in the next two to three years. In that case, the 
Government must set up timelines for the organizations to speed up 
policy implementation [fig. 1]. Necessary steps must also be taken by 
the respective State Governments [22-24]. 
Some states like Telangana, Haryana, Gujarat, and Himachal Pradesh 
have already initiated the allocation of lands for bulk drug 
production. It is the right time for the industries to start building 
facilities [25, 26]. Other supporting measures like tax incentives, 
early clearance from the respective pollution boards, and other 
agencies for the respective companies, must also be initiated. There 
must be uniformity in the policies across all the states of the country 
[25, 27]. The prime key is to implement all these very quickly to 
have a substantial positive impact within the next few years [28]. It 
must also be remembered that the efforts of the government should 
be continued even after the COVID-19 phase to make India a globally 
recognized force in the API industry [29]. 
Our Country needs clear and proactive interventions to ensure an 
all-conducive supply chain. This will not only boost local 
manufacturing but also find ways to reduce dependence on external 
factors. The government launched targeted financial incentives to 
promote the manufacturing of raw materials, and to bring back a 
larger production of APIs to India [30, 31]. The Union Cabinet took a 
decisive step to establish three API parks with common utilities, 
identifying and reducing the dependencies on China for, introduced 
the Production Linked Incentive (PLI) scheme to further reiterate 
India's aim to be self-reliant [32]. The government needs to 
efficiently use existing API units. The shortage of delivery points and 
the lack of accessibility to drugs continue to be bottlenecks even for 
the pharmaceutical companies to fully utilize the domestic market. 
The affordability of drugs will rise due to sustained growth in 
incomes and an increase in insurance coverage [33, 34]. Greater 
spending on healthcare and government-sponsored programs are 
necessary to cover the rural markets. Improving economic growth is 
imperative for investments in healthcare infrastructure and financing, 
and higher per capita disposable income [35]. As various countries are 
willing to invest in the Indian market for the supply of COVID-19 
vaccine and medical equipment, this is the chance for India to become 
truly self-reliant in the pharmaceutical segment [36]. 
CONCLUSION 
For a sustainable market and a robust growth rate, innovative 
business models should be developed for equilibrium in drug price 
controlling and local manufacturing costs regarding the scenario of 
prospects of the API industry which one is very much needed of the 
hour. As well as our Country needs bilateral collaboration, 
multilateral collaboration, to see the need of the society in this crisis 
mode regarding socio-economic point of view, tie-up with various 
good investors, to give emergency service to gear up from the 
present situation, smoothen the export-import challenges, and 
excise issues. Various Countries need to coordinate with each other 
because this pandemic is all about health issues so that the whole 
world can come back to its normal situation from this present 
pandemic situation. To create a special visa for upbringing scientists 
and professionals to grab the opportunity for the production of 
pharmaceutical drugs or equipment at this crucial moment and 
finally to think about regarding less profit from the industrial point 
of view. It is very much necessary for every country leaders to come 
together in one platform, tie up regarding various health 
organizations, do whatever is needed at this crucial hour.  
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